An inter­na­tional team of researchers recently found that people with MGUS who consumed fruit at least three times a week had a lower risk of pro­gress­ing to multiple myeloma than people with MGUS who consumed fruit less frequently.

The impact of higher fruit consumption on risk of pro­gres­sion was sizable. The statistical models developed by the researchers indicate that eating fruit three times or more each week cut the risk of pro­gres­sion by at least a half.

The researchers also found that the risk of devel­op­ing MGUS was about 35 per­cent lower …

Researchers from the Mayo Clinic con­firmed in a recent study that close relatives of people with multiple myeloma have a higher risk of devel­op­ing MGUS (mono­clonal gam­mop­athy of un­determined sig­nif­i­cance) than members of the general pop­u­la­tion.

In particular, the researchers found that "first-degree relatives" – parents, siblings, and children – of people with multiple myeloma were 2.4 times more likely to have MGUS than the general pop­u­la­tion.

This finding is in line with results of a pre­vi­ous Mayo Clinic study, which was smaller but in­cluded some of the same patients and relatives …

Die Ergebnisse einer neuen Studie von Forschern in Deutschland zeigen, dass die monoklonale Leichtketten-Gammopathie unklarer Signifikanz (MGUS) eine sehr geringe Wahrscheinlichkeit hat, zu einem symptomatischen multiplen Myelom fortzuschreiten.

Die deutschen Forscher fanden heraus, dass bei einer medianen Nachbeob­achtungszeit von 11,5 Jahren bei keiner der 75 Personen in ihrer Studie, die eine Leichtketten-MGUS hatten, die MGUS zu einem symptomatischen multiplen Myelom, einer Amyloidose oder einer verwandten Krankheit weiter­entwickelte.

In mehr als der Hälfte der 31 Fälle, in denen die erforderlichen Laborergebnisse vorlagen, wurden die Studienteilnehmer, die zunächst die Kriterien für eine Leichtketten-MGUS-Diagnose erfüllten, …

Light chain mono­clonal gam­mop­athy of undetermined sig­nif­i­cance (MGUS) has a very low probability of progressing to symp­tomatic multiple myeloma, accord­ing to the results of a new study by researchers in Germany.

The German researchers found that, with a median follow-up time of 11.5 years, none of the 75 people in their study who had light chain MGUS saw their MGUS progress to symp­tomatic multiple myeloma, amyloidosis, or a related disease.

In fact, in more than half of the 31 cases where the nec­es­sary laboratory results were avail­able, study par­tic­i­pants who initially met …

Hello, myeloma world. How has your Friday been so far?

We have an eclectic mix of five new myeloma-related research studies that we'd like to discuss with you today.

Three of the studies involve laboratory (preclinical) research, which is the sort of research we often leave to discuss later in these reports. But all three of the laboratory studies we cover today address interesting topics, so we will be looking at them first.

The first laboratory study concerns Darzalex (daratumumab) and the possibility of combining it with an investigational anticancer …

A pleasant weekend to you, myeloma world.

Today is a quiet day in terms of new myeloma-related research and news. We've got just two items in our daily list of new myeloma research, which you can always find at the end of every Myeloma Morning. The article's in today's list are specialized enough that we won't be summarizing them in this report.

We do want to mention, however, that the 2016 annual meeting of the American Association for Cancer Research (AACR) is taking place this weekend and early next …

Good morning, myeloma world.

We hope this Sunday edition of Myeloma Morning finds you rested and ready to do some quick myeloma-related catching up.

We always enjoy reporting on potential new myeloma ther­a­pies, so we thought we'd start today's update with a look at a new study by Korean researchers work­ing at LG Life Sciences. The researchers report results of preclinical (laboratory) tests they have carried out on two drugs, codenamed LC53-0110 and LC53-0151 (full text: html, pdf). Both of these drugs are in the same class of ther­a­pies – …